Poster Sessions

included demographics, sexual behaviour, sex work characteristics and sexual healthcare and a 28-item STI knowledge scale (Jaworski and Carey, 2007). Adjusted prevalence ratios were estimated using poisson regression to assess the association between STI testing in the past year and standardised STI knowledge scores.

Results Participants were aged 18-55 years (Median: 28; IQR: 23-32), all born in Mexico and had been involved in sex trade a median of 6 years (IQR: 3-9). A majority (69%) reported having an STI test in the past year and 39% reporting three or more tests see Abstract P5-S7.15 table 1. Median STI knowledge score was 63% (IQR: 55-70). Notably, 43% and 33% did not think there were cures for Chlamydia and gonorrhoea, respectively. Among the 31% with no STI test, 87% (N=95) indicated that this was because they "had been careful/always used condoms". However, of these, only 44% reported consistent condom use for vaginal sex with non-regular clients. In adjusted regression models accounting for education, income, years in sex work, number of clients and self-treatment, higher STI knowledge scores remained significantly associated with STI testing. Discussion STI knowledge was significantly associated with reporting STI testing in the past year. As women work in bars and brothels outside of the main entertainment district where the majority of FSW interventions are based, STI knowledge may have a greater impact on access and utilisation of testing services. Importantly, misperceptions regarding available treatment and perceptions of sexual risk were prevalent. Incorporation of sexual health education into existing HIV/STI programs is warranted and would be an efficient way to improve sexual healthcare in this population.

Abstract P5-S7.15 Table 1 Prevalence ratios for association of STI testing in past year with standardised STI knowledge score among FSW in Tijuana, Mexico

	STI test past year, N = 277 (69%)	No STI test past year, N=126 (31%)	AdjPR (95% CI)
STI knowledge score			
Median % of responses correctly answered	67 (59—70)	59 (52-67)	_
Median standardised score	0.40 (-0.38, 0.79)	-0.38 (-1.16, 0.40)	1.10 (1.03 to 1.19)
Age <25	84 (30%)	40 (32%)	_
Work colonia			
Region A	131 (47%)	53 (42%)	_
Region B	146 (53%)	73 (58%)	
Lived in TJ whole life	91 (33%)	36 (29%)	_
Education (>6 yrs)	151 (55%)	55 (44%)	1.15 (1.01 to 1.30)
Income (>3500 pesos/mos)	229 (83%)	56 (44%)	1.87 (1.51 to 2.32)
Years of SW	5 (3, 9)	7.5 (3, 11)	0.98 (0.96 to 0.99)
10+ clients/week	158 (57%)	51 (40%)	1.20 (1.06 to 1.37)
Used Antibiotics for STI w/out prescription (ever)	20 (7%)	26 (21%)	0.76 (0.58 to 0.99)

Bold font indicates p<0.05.

P5-S7.16 EASY ACCESS "COMMUNITY-BASED HIV TESTING SERVICES FOR GAY MEN: A SYSTEMATIC REVIEW"

doi:10.1136/sextrans-2011-050108.611

Background Community-based HIV testing has been widely utilised with the goal of increasing testing opportunities for gay men and decreasing the number of men who are unaware of their HIV status.

Abstract P5-S7.16 Table 1 Summary of community HIV testing services by setting and key outcomes of interest (n=44)

USA	Category	Subcategory	All services n (%)
Spain 1 (2.3)	Location (n=44)	Australia	3 (6.8)
Switzerland		Hong Kong	1 (2.3)
The Netherlands		Spain	1 (2.3)
New Zealand		Switzerland	1 (2.3)
UK USA 28 (63.6) USA 28 (63.6) 15 (34.6) 15 (34.6) 15 (34.6) 15 (34.6) 15 (34.6) 16 (35.6) 17 (36.8) 18 (36.8) 19 (36.8) 10 (36.		The Netherlands	3 (6.8)
USA 28 (63.6) Flarget group (n=44)† Men who have sex with men (only) 15 (34.6) Broader population including: MSM 6 (13.6) Ethnic minority 3 (6.8) Transgender 3 (6.8) Transgender 3 (6.8) Multiple 3 (6.8) Multiple 11 (25.0) Not reported 3 (6.8) Service type (n=44) On-site CBO 8 (18.2) Community clinic* 10 (25.0) Outreach Mobile testing facility (MTF) 6 (13.6) Venue-based outreach (bar, club, sauna) Multiple sites (venues, MTF, homeless shelter) On-site and outreach services (combination of venues) Number of sites (n=44) 1–2 29 (65.9) Number of sites (n=44) 1–2 29 (65.9) For 10 2 (4.6) Multiple sites -number not reported 12 (27.3) Not Specified 12 (27.3) Not Specified 12 (22.3) Not Specified 12 (22.3) Not Specified 12 (22.3) Not Specified 13 (10.7) Type of Rapid Abbott Determine HIV-1/2 rapid test 12 (42.9) OraSure OraQuick Advance Rapid HIV-1/2 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Operating hours (n=16) 2-5 h/week 5-10 h/week 5-25 h/week 5-10 h/week 5-25 h/week 5-10 h/week 5-27 h/week 5-10 h/week 5-27 h/week 5-10 h/week 5-		New Zealand	1 (2.3)
Men who have sex with men (only) 15 (34.5)		UK	6 (13.6)
Broader population including: MSM 6 (13.6) Ethnic minority 3 (6.8) Young people 3 (6.8) Transgender 3 (6.8) IDUS 3 (6.8) Multiple 11 (25.0) Not reported 3 (6.8) Multiple 11 (25.0) Not reported 3 (6.8) Not reported 3 (6.8) Multiple 10 (25.0) Outreach Mobile testing facility (MTF) 6 (13.6) Outreach Mobile sites (venues, MTF, homeless shelter) On-site and outreach services (combination of venues) On-site and outreach venues) On-site and outreach venues On-site and outr		USA	28 (63.6)
MSM	Target group (n=44)†		15 (34.6)
Ethnic minority Young people Young people Transgender JOUS Multiple Multiple Not reported On-site CBO Community clinic* Outreach Mobile testing facility (MTF) Venue-based outreach (bar, club, sauna) Multiple sites (venues, MTF, homeless shelter) On-site and outreach services (combination of venues) Number of sites (n=44) No reside and outreach services (combination of venues) Number of sites (n=44) No Specified Rapid HIV testing Pes in parallel with conventional EIA testing No 10 (22.7) Type of Rapid Abbott Determine HIV-1/2 rapid test Pesting (n=28)† † Abbott-Murex Single Use Diagnostic System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK OraSure OraQuick Advance Rapid HIV-1/2 Antibody OraSure OraQuick Advance Rapid HIV-1/2 Antibody OraSure OraQuick Advance Rapid HIV-1/2 Antibody Unigold Recombigen HIV Operating hours (n=16) Operating hours (n=16) Staff types (n=26)† Administrative staff HIV counselling & testing staff/counsellors Nurses/healthcare workers/clinic co-ordinator Phlebotomists Physicians/medical officers Physicians/medical officers Physicians/medical officers Physicians/medical officers Physicians/medical officers Physicians/medical officers Nurses/healthcare workers/clinic co-ordinator Sexual health educators/peer-workers/outreach workers Social workers/case managers Volunteers Social workers/case managers Volunteers Social workers/case managers Volunteers			6 (13.6)
Young people		Ethnic minority	
Transgender 10Us 3 (6.8) IDUS 3 (6.8) Multiple 11 (25.0) Not reported 3 (6.8) Service type (n=44) On-site CBO 8 (18.2) Community clinic* 10 (25.0) Outreach Mobile testing facility (MTF) 6 (13.6) Venue-based outreach (bar, club, sauna) Multiple sites (venues, MTF, homeless shelter) 7 (15.9) venue-based outreach services (combination of venues) Number of sites (n=44) 1−2 29 (65.9) 5−10 2 (4.6) Multiple sites −number not reported 12 (27.3) Not Specified 1 (2.3) Not Specified 1 (2.3) Inverness Cleariem HIV-1/2 rapid test 12 (42.9) Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6) OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Cost to patient (n=32) Nil - (covered by service/study) 17 (38.6) Staff types (n=26) † Administrative staff HIV counselling & testing staff/counsellors 16 (6.1.5) Nurses/healthcare workers/clinic co-ordinator Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Physicians/m			
IDUS Multiple 11 (25.0)			
Multiple Not reported 3 (6.8) Not reported 3 (6.8) On-site CBO 8 (18.2) Community clinic* 10 (25.0) Venue-based outreach (bar, club, sauna) 8 (18.2) Multiple sites (venues, MTF, homeless shelter) 5 (11.4) On-site and outreach services (combination of venues) Number of sites (n=44) 1−2 29 (65.9) Multiple sites—number not reported 12 (27.3) Not Specified 1 (2.3) Not Specified 1 (2.3) Rapid HIV testing Yes 30 (68.2) Yes in parallel with conventional EIA testing No 10 (22.7) No 10 (22.7) Inverness Clearview HIV-1/2 rapid test 12 (42.9) Abbott Determine HIV-1/2 rapid test 12 (42.9) Festing (n=28)†		•	
Not reported 3 (6.8)			
Service type (n=44) On-site CBO Community clinic* Outreach Mobile testing facility (MTF) Venue-based outreach (bar, club, sauna) Multiple sites (venues, MTF, homeless shelter) On-site and outreach services (combination of venues) Number of sites (n=44) Nor Specified Testing (n=44) Ves in parallel with conventional EIA testing No Nor Specified Abbott Determine HIV-1/2 rapid test Testing (n=28)† ‡ Abbott-Murex Single Use Diagnostic System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK OraSure OraQuick Advance Rapid HIV-1/2 Antibody Unigold Recombigen HIV OraSure OraQuick Rapid HIV-1/2 Antibody Unigold Recombigen HIV OraSure OraQuick Rapid HIV-1/2 Antibody Unigold Recombigen HIV Operating hours (n=16) Deperating hours (n=16) Staff types (n=26)† Administrative staff HIV counselling & testing staff/counsellors Nurses/healthcare workers/clinic co-ordinator Phlebotomists Physicians/medical officers Physicians/medical officers Physicians/medical officers Physicians/medical officers Physicians/medical officers Physicians/medical officers Social workers/case managers Volunteers Venus (11.4) 10 (25.0) 11 (25.0) 12 (27.3) 13 (68.4)		•	
Community clinic* 10 (25.0) Outreach Mobile testing facility (MTF) 6 (13.6) Venue-based outreach (bar, club, sauna) 8 (18.2) Multiple sites (venues, MTF, homeless shelter) 7 (15.9) Number of sites (n=44) 1−2 29 (65.9) Multiple sites—number not reported 12 (27.3) Not Specified 1 (2.3) Rapid HIV testing Yes 30 (68.2) Yes in parallel with conventional EIA testing 4 (9.1) No 10 (22.7) Abbott Determine HIV-1/2 rapid test 12 (42.9) Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6) OraSure OraQuick Advance Rapid HIV-1/2 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Operating hours (n=16) 2−5 h/week 10 (62.5) 5−10 h/week 5-10 h/week 5 (31.3) Staff types (n=26)† Administrative staff HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator Phlebotomists Psychotherapists Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) 2−3 13 (68.4)	Service type (n-11)	'	
Outreach Mobile testing facility (MTF) 6 (13.6) Venue-based outreach (bar, club, sauna) 8 (18.2) Multiple sites (venues, MTF, homeless shelter) 5 (11.4) On-site and outreach services (combination of venues) 7 (15.9) Number of sites (n=44) 1-2 29 (65.9) 5−10 2 (4.6) Multiple sites—number not reported 12 (27.3) Not Specified 1 (2.3) 30 (68.2) Rapid HIV testing Yes 30 (68.2) Yes in parallel with conventional EIA testing 4 (9.1) No 10 (22.7) Abbott Determine HIV-1/2 rapid test 12 (42.9) Type of Rapid Abbott-Murex Single Use Diagnostic 3 (10.7) System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6) OraSure OraQuick Advance Rapid HIV-1/2 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Cost to patient (n=32) Nil - (covered by service/study) 17 (38.6) Nil - (covered by service/study) 17 (38.6) Nil - (week 5-10 h/week 5 (31.3) 5-10 h/week 5 (31.3)	service type (II—44)		
Venue-based outreach (bar, club, sauna) Multiple sites (venues, MTF, homeless shelter) 5 (11.4)		,	
Multiple sites (venues, MTF, homeless shelter) On-site and outreach services (combination of venues) Number of sites (n=44) Number of sites (n=44) 1-2 5-10 Multiple sites—number not reported 12 (27.3) Not Specified 1 (2.3) Rapid HIV testing Offered (n=44) Yes in parallel with conventional EIA testing No No 10 (22.7) No Ivpe of Rapid Abbott Determine HIV-1/2 rapid test Abbott-Murex Single Use Diagnostic System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK OraSure OraQuick Advance Rapid HIV-1/2 Antibody Unigold Recombigen HIV Orasure OraQuick Rapid HIV-1 Antibody Unigold Recombigen HIV Operating hours (n=32) Nil - (covered by service/study) Nil + incentive received for participating Staff types (n=26) † Administrative staff HIV counselling & testing staff/counsellors Nurses/healthcare workers/clinic co-ordinator Phlebotomists Physicians/medical officers Psychotherapists Sexual health educators/peer-workers/outreach workers Social workers/case managers Volunteers Volunteers Volunteers Volunteers Volunteers Volunteers Visite and outreach services (combination of (15.3) 13 (68.4)			
On-site and outreach services (combination of venues) Number of sites (n=44) 1-2 29 (65.9) 5-10 2 (4.6) Multiple sites—number not reported 12 (27.3) Not Specified 1 (2.3) Rapid HIV testing Yes 30 (68.2) Yes in parallel with conventional EIA testing 4 (9.1) No 10 (22.7) Ivpe of Rapid Abbott Determine HIV-1/2 rapid test 12 (42.9) Abbott-Murex Single Use Diagnostic 3 (10.7) System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6) OraSure OraQuick Advance Rapid HIV-1/2 Antibody 12 (42.9) OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Cost to patient (n=32) Nil - (covered by service/study) 17 (38.6) Nil + incentive received for participating 11 (25.0) \$10 -€20 payment for test 4 (11.4) Operating hours (n=16) 2-5 h/week 10 (62.5) 5-10 h/week 5 (31.3) Staff types (n=26)† Administrative staff HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator Phlebotomists Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Psychotherapists Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 13 (68.4)			
Number of sites (n=44) 1—2 29 (65.9) 5—10 2 (4.6)		On-site and outreach services (combination of	7 (15.9)
5—10 Multiple sites—number not reported Not Specified 12 (27.3) Not Specified 1 (2.3) Rapid HIV testing Offered (n=44) Yes in parallel with conventional EIA testing No	Number of sites (n. 44)	,	20 (65 0)
Multiple sites—number not reported 12 (27.3)	vulliber of sites (n=44)		
Not Specified 1 (2.3)			
Rapid HIV testing offered (n=44) Yes in parallel with conventional EIA testing 4 (9.1) No 10 (22.7) Type of Rapid Abbott Determine HIV-1/2 rapid test 12 (42.9) Testing (n=28)† ‡ Abbott-Murex Single Use Diagnostic System for HIV-1 [SUDS] 3 (10.7) Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6) OraSure OraQuick Advance Rapid HIV-1/2 Antibody Unigold Recombigen HIV 4 (14.3) Cost to patient (n=32) Nil - (covered by service/study) 17 (38.6) Nil + incentive received for participating \$11 (25.0) 11 (25.0) \$10—€20 payment for test 4 (11.4) Operating hours (n=16) 2—5 h/week 10 (62.5) 5—10 h/week 5 (31.3) Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers 9 (34.6) No Staff/shift (n=19) 1 1 (5.3) 2—3 13 (68.4) </td <td></td> <td></td> <td></td>			
Offered (n=44) Yes in parallel with conventional EIA testing No 10 (22.7) No Type of Rapid Abbott Determine HIV-1/2 rapid test Abbott-Murex Single Use Diagnostic System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK OraSure OraQuick Advance Rapid HIV-1/2 Antibody Unigold Recombigen HIV Operating hours (n=32) Nil - (covered by service/study) \$\frac{1}{3}\$ (10.7) \$\frac{3}{3}\$ (10.7) Cost to patient (n=32) Nil - (covered by service/study) \$\frac{1}{3}\$ (10.7) \$\frac{3}{3}\$ (10.7) Cost to patient (n=32) Nil - (covered by service/study) \$\frac{1}{3}\$ (10.7) \$\frac{3}{3}\$ (10.7) Cost to patient (n=32) Nil - (covered by service/study) \$\frac{1}{3}\$ (10.7) \$\frac{3}{3}\$ (10.7) \$\frac{3}{		·	
No 10 (22.7) No 10 (22.7) No 10 (22.7) No 10 (22.7) Abbott Determine HIV-1/2 rapid test 12 (42.9) Abbott-Murex Single Use Diagnostic 3 (10.7) System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6) OraSure OraQuick Advance Rapid HIV-1/2 Antibody 12 (42.9) OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Nil - (covered by service/study) 17 (38.6) Nil + incentive received for participating 11 (25.0) \$10—€20 payment for test 4 (11.4) Operating hours (n=16) 2—5 h/week 10 (62.5) 5—10 h/week 5 (31.3) >10 h/week 5 (31.3) Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) 2—3 13 (68.4)			
Type of Rapid Festing (n=28)† ‡ Abbott Determine HIV-1/2 rapid test 12 (42.9) Festing (n=28)† ‡ Abbott-Murex Single Use Diagnostic System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6) OraSure OraQuick Advance Rapid HIV-1/2 Antibody 12 (42.9) OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Cost to patient (n=32) Nil - (covered by service/study) 17 (38.6) Nil + incentive received for participating 11 (25.0) \$10—€20 payment for test 4 (11.4) Operating hours (n=16) 2—5 h/week 10 (62.5) 5—10 h/week 5 (31.3) Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) 2—3 13 (68.4)	mereu (n—44)	·	
Festing (n=28)† ‡ Abbott-Murex Single Use Diagnostic System for HIV-1 [SUDS] 3 (10.7) System for HIV-1 [SUDS] Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6) OraSure OraQuick Advance Rapid HIV-1/2 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) (14.3) Unigold Recombigen HIV 4 (14.3) (14.3) (15.4) Unigold Recombigen HIV 4 (14.3) (14.3) (15.4) (15			
Inverness Clearview HIV 1/2 STAT-PAK 1 (3.6)		Abbott-Murex Single Use Diagnostic	12 (42.9) 3 (10.7)
OraSure OraQuick Advance Rapid HIV-1/2 Antibody 12 (42.9) OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Cost to patient (n=32) Nil - (covered by service/study) 17 (38.6) Nil + incentive received for participating 11 (25.0) \$10—€20 payment for test 4 (11.4) Operating hours (n=16) 2−5 h/week 10 (62.5) 5−10 h/week 5 (31.3) >10 h/week 5 (31.3) >10 h/week 5 (31.3) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers 9 (34.6) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)			1 (0.0)
OraSure OraQuick Rapid HIV-1 Antibody 10 (35.7) Unigold Recombigen HIV 4 (14.3) Cost to patient (n=32) Nil - (covered by service/study) 17 (38.6) Nil + incentive received for participating 11 (25.0) \$10 — €20 payment for test 4 (11.4) Operating hours (n=16) 2-5 h/week 10 (62.5) 5-10 h/week 5 (31.3) >10 h/week 5 (31.3) Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers 9 (34.6) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)			
Unigold Recombigen HIV 4 (14.3) Nil - (covered by service/study) 17 (38.6) Nil + incentive received for participating 11 (25.0) \$10—€20 payment for test 4 (11.4) Operating hours (n=16) 2—5 h/week 10 (62.5) 5—10 h/week 5 (31.3) >10 h/week 5 (31.3) Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2—3 13 (68.4)			
Cost to patient (n=32) Nil - (covered by service/study) 17 (38.6) Nil + incentive received for participating 11 (25.0) \$10—€20 payment for test 4 (11.4) Operating hours (n=16) 2–5 h/week 10 (62.5) 5–10 h/week 1 (6.3) >10 h/week 5 (31.3) Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers 9 (34.6) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)		· · · · · · · · · · · · · · · · · · ·	
Nil + incentive received for participating 11 (25.0) \$10—€20 payment for test 4 (11.4) Operating hours (n=16) 2–5 h/week 10 (62.5) 5—10 h/week 1 (6.3) >10 h/week 5 (31.3) Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers 9 (34.6) Workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 (5.3) 2—3 13 (68.4)		0	
\$10—€20 payment for test 4 (11.4) Operating hours (n=16) 2-5 h/week 10 (62.5) 5-10 h/week 1 (6.3) >10 h/week 5 (31.3) Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)	Cost to patient (n=32)	· · · · · · · · · · · · · · · · · · ·	, ,
Departing hours (n=16) 2-5 h/week 10 (62.5) 5-10 h/week 1 (6.3) >10 h/week 5 (31.3) > 10 h/week 5 (31.3			
5—10 h/week 1 (6.3) >10 h/week 5 (31.3) Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2—3 13 (68.4)			
Staff types (n=26) Administrative staff	Operating hours (n=16)		10 (62.5)
Staff types (n=26)† Administrative staff 4 (15.4) HIV counselling & testing staff/counsellors 16 (61.5) Nurses/healthcare workers/clinic co-ordinator 8 (30.8) Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers 9 (34.6) Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)		5—10 h/week	1 (6.3)
HIV counselling & testing staff/counsellors Nurses/healthcare workers/clinic co-ordinator Phlebotomists Physicians/medical officers Psychotherapists 2 (7.7) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers Volunteers 4 (15.4) 4 (15.4) 1 (15.4) 1 (15.4) 1 (15.4) 1 (15.4) 1 (15.4) 2 (17.7)		>10 h/week	5 (31.3)
Nurses/healthcare workers/clinic co-ordinator 8 (30.8)	Staff types (n=26)†	Administrative staff	4 (15.4)
Phlebotomists 2 (7.7) Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)		HIV counselling & testing staff/counsellors	16 (61.5)
Physicians/medical officers 4 (15.4) Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)		Nurses/healthcare workers/clinic co-ordinator	8 (30.8)
Psychotherapists 2 (7.7) Sexual health educators/peer-workers/outreach workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)		Phlebotomists	2 (7.7)
Sexual health educators/peer-workers/outreach workers 9 (34.6)		Physicians/medical officers	4 (15.4)
workers Social workers/case managers 2 (7.7) Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)		Psychotherapists	2 (7.7)
Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)		· · · · · · · · · · · · · · · · · · ·	9 (34.6)
Volunteers 4 (15.4) No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)		Social workers/case managers	2 (7.7)
No Staff/shift (n=19) 1 1 (5.3) 2-3 13 (68.4)			4 (15.4)
2–3 13 (68.4)	No Staff/shift (n=19)	1	
•	• •	2–3	13 (68.4)
4-7 5 (20.3)		4-7	5 (26.3)

^{*}Community clinics refer to services that offer direct medical services to clients; for example, STI/HIV testing and treatment, vaccinations, dental services and may have a licensed pharmacies or laboratory on-site.

¹A Pedrana, ¹M Stoove, ¹A Bowring, ¹M Hellard, ²R Guy. ¹Burnet Institute, Melbourne, Australia; ²National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia

 $[\]dagger$ Target group, type of rapid test and staffing types are not mutually exclusive, so percentages do not add up to 100%.

 $[\]pm$ Some studies reported offering more than type of rapid test, therefore numbers do not add up to n=28.

Yet there remains ongoing debate as to whether such models offer advantages over routine clinical services. As such, there has been low uptake of community-based HIV testing in some countries. To better understand the processes and outcomes of these programs to inform future implementation, we systematically reviewed published studies.

Methods We searched Medline, EMBASE and Cochrane databases from 1980 to October 2010. Included studies described HIV testing outcomes of community based testing services that included gay men as clients. The primary outcomes were client testing history and HIV positivity.

Results We identified 33 papers that described 44 community-based HIV testing services. There were 18 on-site only services (community based organisations/community clinics, including one multi-fixed site), seven on-site services with outreach and 19 outreach only services, including eight outreach services in venues (bar, club, sauna); six mobile testing facilities and five community outreach sites in multiple locations (See Abstract P5-S7.16 table 1). The majority of the services were in the US (28 of 44) and 34 of 44 offered rapid HIV antibody testing on-site at the point-of-care. OraQuick Advance Rapid HIV-1/2 Antibody or Abbott Determine HIV-1/2 rapid with finger-stick were the most common tests used. Among services reporting testing outcomes specifically for gay men (22 of 44), the median proportion of men who had never tested for HIV prior to attending the community-based testing service was 34.1% (range: 7.8%-44.0% per service). The median HIV positivity was 3.9% (range: 0.3%-60.0% per service) and the median return rate for confirmatory testing was 83.8% (range: 22.7%-95.0% per service); higher in community-based organisation services (84.2%) and lower in outreach models (33.0%).

Conclusion Community-based HIV testing services provide a model of HIV testing that attracts a significant proportion of gay men who have never tested before, and these men are at high risk of HIV as evidenced by the HIV positivity rate.

P5-S7.17

ACCEPTING THE GOOD WITH THE BAD: "BARRIERS AND FACILITATORS OF COMMUNITY-BASED HIV TESTING SERVICES FOR GAY MEN: A SYSTEMATIC REVIEW"

doi:10.1136/sextrans-2011-050108.612

¹A Pedrana, ¹M Stoove, ¹A Bowring, ¹M Hellard, ²R Guy. ¹Burnet Institute, Melbourne, Australia; ²National Centre in HIV Epidemiology and Clinical Research Sydney Australia

Background With a global focus on increased HIV testing among high risk groups including men who have sex with men (MSM), many community-based HIV testing services have been established in recent years with the goal of increasing testing opportunities for populations at risk. To better understand the acceptability of community based HIV testing models targeting MSM from the provider and consumer perspective we systematically reviewed published studies.

Methods We searched Medline, EMBASE and Cochrane databases from 1980 to October 2010. Studies were included if they described acceptability of community based HIV testing services targeting MSM, including outreach settings (eg, saunas, public events), collected through surveys, in-depth interviews, focus groups, or exit forms. A quantitative descriptive analysis of the barriers and facilitators of community based HIV testing identified by service providers and consumers was conducted.

Results We identified 25 papers that met our selection criteria and were included in the review see Abstract P5-S7.17 table 1. Twenty one studies focused on facilitators from the consumers' perspective, with testing convenience, provision of rapid testing,

and acceptability/feeling comfortable with settings reported at factors that facilitated seeking HIV testing at community based services. From the provider perspective (six studies) key factors enhancing service acceptability were client friendly protocols, service promotion, offering additional clinical services, and effective protocols for follow-up and referral. Sixteen studies captured barriers to using community based HIV testing services from the consumer perspective and the main issue reported related to readiness to receive results on the same day or in the community-based environment. Providers in six studies reported difficulties in follow-up, testing in outreach settings, cost, providing adequate staff training, managing workload and developing and maintaining referral pathways as key barriers.

Conclusion Acceptability from both consumers and service providers is important to ensure an efficient and sustainable service. The experiences of many other services collated in this review will help other organisations address potential barriers and facilitators to the implementation of community-based HIV testing services.

Abstract P5-S7.17 Table 1 Summary of community HIV testing services (sample size) (n=25)

Category	Subcategory	All services n (%
Location	Canada	1 (4.0)
	Hong Kong	1 (4.0)
	New Zealand	1 (4.0)
	Switzerland	1 (4.0)
	The Netherlands	3 (12.0)
	UK	3 (12.0)
	USA	15 (60.0)
Target group	MSM	15 (60.0)
	Multiple	7 (28.0)
	Unclear — CBO clients	3 (12.0)
Services type*	CBO/community centre	10 (40.0)
	STD clinic	3 (12.0)
	Mobile testing facility	1 (4.0)
	Needle exchange programs	2 (8.0)
	Venue-based outreach (bar, club, sauna)	9 (36.0)
	Combination (eg, CBO, outreach, mobile testing facility).	5 (20.0)
Rapid testing	Yes	13 (52.0)
offered	No	5 (20.0)
	Yes— in combination with standard testing	4 (16.0)
	Unclear	3 (12.0)
Study design	Case studies	1 (4.0)
	Clinical audit	1 (4.0)
	Cross-sectional studies	4 (16.0)
	Evaluation reports	4 (16.0)
	Pilot/feasibility studies	4 (16.0)
	Qualitative studies	10 (40.0)
	Randomised trails (RCT)	1 (4.0)
Data collection	Client surveys (including exit forms)	15 (60.0)
methods*	Focus groups	2 (8.0)
	In-depth interviews	5 (20.0)
	Provider surveys	2 (8.0)
	Qualitative phone interviews	3 (12.0)
Study participants	Clients	17 (68.0)
	Providers	4 (16.0)
	Clients & providers	4 (16.0)

^{*}Service types and data collection methods are not mutually exclusive, so % do not add to 100%